UNSPSC 51271503: Hyaluronidase

This classification denotes an adjuvant with the molecular formula C2327H3553N589O667S20, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8KOG53Z5EM, more generally known as hyaluronidase. European Medicines Agency schedules hyaluronidase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02552MIG. The term HYALURONIDASE is an International Non-Proprietary Name or INN. HYALURONIDASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule hyaluronidase under HS 35079090 and SITC 51691. As of Q4 2014, HYALURONIDASE remains the US FDA Preferred Term for this commodity. Hyaluronidase bears US NLM identifiers UMLS ID C0020197 and NCI Concept Code C87576. SMILES: NONE.

UNSPSC 51271503 Hyaluronidase is a Commodity code representing injectable enzyme products used in medical and pharmaceutical applications. State and local government purchasing under this code centers on pharmaceutical procurement through cooperative purchasing vehicles and multi-source generic drug agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits manufacturers and suppliers of generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities. Issuing bodies include state health and human services departments, state prison systems, and local hospital networks that leverage cooperative agreements to achieve volume pricing and standardized sourcing. MMCAP's structure—requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and comply with cGMP and Drug Supply Chain Security Act (DSCSA) requirements—reflects the regulatory and operational complexity typical of state pharmaceutical procurement at scale.

Recent activity is concentrated in the Upper Midwest and Pacific Northwest, with MMCAP's multi-state footprint spanning Minnesota, Oregon, and other participating jurisdictions. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, seeking manufacturers to supply generic pharmaceuticals with specific National Drug Codes, SKUs, UPCs, and documented manufacturing locations. Evaluation weights pricing competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, EDI capability, administrative fee compliance, and format adherence. The contract term runs two years for new vendors with optional extensions, or through June 30, 2028, for incumbent amendments. Vendors must carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. No set-aside designations are disclosed in available solicitation materials. MMCAP reserves award flexibility—sole, dual, or multi-awards—based on therapeutic considerations and member-specific needs, with performance penalties ranging from $200 to $1,500 per violation for late reporting, onboarding delays, or improper class-of-trade denials.